Market Cap 68.39M
Revenue (ttm) 0.00
Net Income (ttm) -117.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 102,184
Avg Vol 207,649
Day's Range N/A - N/A
Shares Out 9.58M
Stochastic %K 37%
Beta 1.58
Analysts Strong Sell
Price Target $28.25

Company Profile

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmun...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 503 9095
Address:
131 Dartmouth Street, 3rd Floor, Boston, United States
__ChartMenace
__ChartMenace Feb. 23 at 12:17 PM
0 · Reply
_PikaPlays
_PikaPlays Feb. 19 at 5:28 PM
0 · Reply
Sunny3999
Sunny3999 Feb. 18 at 5:20 PM
0 · Reply
MultiStrategyMind
MultiStrategyMind Feb. 18 at 4:33 PM
$ACET Adicet Bio develops allogeneic cell therapies. Clinical milestones drive valuation. Cash runway defines downside.
0 · Reply
BreakoutPika
BreakoutPika Feb. 18 at 12:27 PM
0 · Reply
BreakoutPika
BreakoutPika Feb. 17 at 6:08 PM
0 · Reply
MoneyAtlas
MoneyAtlas Feb. 17 at 4:37 PM
$ACET big catalyst coming.
1 · Reply
MarketMetronome
MarketMetronome Feb. 17 at 3:38 PM
$ACET Aceto develops generic pharmaceuticals and specialty chemicals, with restructuring efforts and competitive pressures.
0 · Reply
_PikaPlays
_PikaPlays Feb. 17 at 12:51 PM
1 · Reply
Klamalsnn
Klamalsnn Feb. 13 at 6:40 AM
$ACET did shit Hit the Fan? They startet New Dose Level in SLE LN, something they didnt plan in october. So we should have Seen Weak durability in Patients presented in october
1 · Reply
Latest News on ACET
Adicet Bio Announces Reverse Stock Split

Fri, 26 Dec 2025 08:30:00 -0500 - 2 months ago

Adicet Bio Announces Reverse Stock Split


Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Fri, 28 Nov 2025 14:23:00 -0500 - 3 months ago

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)


Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 31 Oct 2025 16:59:00 -0400 - 4 months ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)


Adicet Bio, Inc. - Special Call

Tue, 07 Oct 2025 12:35:19 -0400 - 4 months ago

Adicet Bio, Inc. - Special Call


Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

Tue, 07 Oct 2025 07:01:00 -0400 - 4 months ago

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering


Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Tue, 30 Sep 2025 16:27:00 -0400 - 5 months ago

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)


Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 29 Aug 2025 16:48:00 -0400 - 6 months ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)


Adicet Bio (ACET) Q2 Loss Widens 3%

Thu, 07 Aug 2025 16:14:10 -0400 - 7 months ago

Adicet Bio (ACET) Q2 Loss Widens 3%


Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Wed, 30 Apr 2025 16:47:00 -0400 - 10 months ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)


Adicet Bio Appoints Michael Grissinger to the Board of Directors

Thu, 17 Apr 2025 07:00:00 -0400 - 11 months ago

Adicet Bio Appoints Michael Grissinger to the Board of Directors


Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 31 Mar 2025 17:12:00 -0400 - 11 months ago

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Wed, 18 Dec 2024 07:00:00 -0500 - 1 year ago

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer


Adicet Bio to Participate in Upcoming Investor Conferences

Fri, 01 Nov 2024 07:00:00 -0400 - 1 year ago

Adicet Bio to Participate in Upcoming Investor Conferences


__ChartMenace
__ChartMenace Feb. 23 at 12:17 PM
0 · Reply
_PikaPlays
_PikaPlays Feb. 19 at 5:28 PM
0 · Reply
Sunny3999
Sunny3999 Feb. 18 at 5:20 PM
0 · Reply
MultiStrategyMind
MultiStrategyMind Feb. 18 at 4:33 PM
$ACET Adicet Bio develops allogeneic cell therapies. Clinical milestones drive valuation. Cash runway defines downside.
0 · Reply
BreakoutPika
BreakoutPika Feb. 18 at 12:27 PM
0 · Reply
BreakoutPika
BreakoutPika Feb. 17 at 6:08 PM
0 · Reply
MoneyAtlas
MoneyAtlas Feb. 17 at 4:37 PM
$ACET big catalyst coming.
1 · Reply
MarketMetronome
MarketMetronome Feb. 17 at 3:38 PM
$ACET Aceto develops generic pharmaceuticals and specialty chemicals, with restructuring efforts and competitive pressures.
0 · Reply
_PikaPlays
_PikaPlays Feb. 17 at 12:51 PM
1 · Reply
Klamalsnn
Klamalsnn Feb. 13 at 6:40 AM
$ACET did shit Hit the Fan? They startet New Dose Level in SLE LN, something they didnt plan in october. So we should have Seen Weak durability in Patients presented in october
1 · Reply
BearDiver
BearDiver Feb. 10 at 2:22 PM
$ACET is a biotech (Adicet Bio) developing cell therapies; high-risk, early-stage pipeline.
0 · Reply
BioTechChap
BioTechChap Feb. 9 at 2:33 PM
$ACET Some smart bargain buying going on here
2 · Reply
beatn23
beatn23 Feb. 4 at 11:24 AM
$ACET The most dangerous part of ACET's 1:16 split is that they kept their Authorized Shares at 300 million. Before the split, they had 153 million shares out. After the split, they only have 9.6 million shares out. The Catch: They now have the legal right to sell 290 million new shares whenever they want. This is "Dilution Power." If they start selling those shares to raise cash, the price will drop to $2.00 faster than most people think.
2 · Reply
beatn23
beatn23 Feb. 4 at 11:20 AM
$ACET I would never buy ACET at post - split price, this will go down like nothing very soon. When ACET did 1:16, they have no faith in the science , they just want to prolong the stay on NASDAQ, same saga for both OTLK and ATRA , they too went nuclear on reverse spilt, look where they are now, OTLK(1:20) is facing risk of deilisting , ATRA(1:25), running out of cash after FDA reject. Same fate will fall on ACET- 1:16 is really ballistic, the price will crasht o 1 or 1.50, it is only a matter of time when companies do reverse splitts that high. Guys be extra careful with ACET, just do not buy the spikes !
0 · Reply
Sunny3999
Sunny3999 Feb. 3 at 4:15 PM
$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $ACET $PAVM $PMNT $RVPH
2 · Reply
Sunny3999
Sunny3999 Jan. 30 at 1:21 PM
$PMN Wow ripping with news $175 million private placement https://www.promisneurosciences.com/news-media/press-releases/detail/261/promis-neurosciences-announces-up-to-175-million-private $ACET $PAVM $PMNT $RVPH
0 · Reply
aletz
aletz Jan. 30 at 1:14 PM
$ACET Feb Wk 1 AI Scanner https://www.biostockinfo.com/biotech-catalyst-ai-scanner-february-wk1/
2 · Reply
THSSKS
THSSKS Jan. 27 at 3:27 PM
$ACET started a small position here. It’s junk but $10+ in cash
1 · Reply
BillionerOfKing
BillionerOfKing Jan. 27 at 2:12 AM
$ACET Current Stock Price: $8.66 Contracts to trade: $10 ACET Feb 20 2026 Call Entry: $0.50 Exit: $0.91 ROI: 84% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
1 · Reply
pc247cz
pc247cz Jan. 26 at 3:49 PM
$ACET C'mon
0 · Reply
peepthestamp
peepthestamp Jan. 25 at 8:09 PM
$ACET $PAVM $PMN $PMNT $RVPH -Aging well 🫡
0 · Reply
BioTechChap
BioTechChap Jan. 22 at 9:51 PM
$ACET Matter of time until we see this one getting some traction
0 · Reply